1 BTC
=
- USD
ArriVent BioPharma, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Market Statistics
Trading Metrics
How to Buy AVBP
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy AVBP
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesArriVent BioPharma received FDA IND clearance for ARR-002, a first-in-class dual-target antibody-drug conjugate targeting MUC16 and NaPi2b for ovarian and endometrial cancers. Preclinical data presented at AACR 2026 demonstrated superior efficacy and favorable tolerability compared to single-target ADCs. Phase 1 trial initiation is expected in the second half of 2026.
ArriVent BioPharma announced two preclinical poster presentations at the 2026 AACR Annual Meeting. The company will present data on firmonertinib, an EGFR inhibitor showing activity against classical and exon 20 insertion mutations with ongoing Phase 3 trials, and ARR-002, a dual-target MUC16/NaPi2b tetravalent ADC developed in partnership with Aarvik Therapeutics demonstrating superior anti-tumor activity in ovarian and endometrial cancer models.
The FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significant survival benefits in colorectal cancer, Relay's zovegalisib receiving Breakthrough designation for breast cancer, MAIA's ateganosine advancing in lung cancer, Zai Lab's AUGTYRO approval in China, and Arrivent's firmonertinib entering pivotal Phase 3 trials for NSCLC.
The oncology landscape is experiencing rapid regulatory advancement as precision medicine and genomics expand significantly. Multiple biotech companies are advancing cancer therapies toward accelerated FDA approvals in 2026, with the precision medicine market projected to grow from $138.67 billion in 2026 to $537.17 billion by 2035. Key developments include Oncolytics' pelareorep showing strong response rates in anal cancer, CG Oncology's Phase 3 trial ahead of schedule, Zentalis advancing azenosertib in ovarian cancer, ArriVent initiating a pivotal Phase 3 study for firmonertinib, and PDS Biotechnology gaining FDA alignment on trial endpoints.
ArriVent BioPharma announced the first patient dosing in the Phase 3 ALPACCA pivotal trial evaluating firmonertinib for first-line treatment of EGFR PACC mutant NSCLC. The trial compares firmonertinib 240 mg once daily against osimertinib or afatinib, with primary endpoints of overall response rate and progression-free survival. The company estimates approximately 42,000 patients globally and 6,200 in the US annually with this mutation type.